Alkylation of prohibitin by cyclohexylphenyl-chloroethyl urea on an aspartyl residue is associated with cell cycle G 1 arrest in B16 cells

British Journal of Pharmacology

Volumn 152, Issue 4, 2007, Pages 449-455

  Bouchon, B ^a   Papon, J ^b   Communal, Y ^c   Madelmont, J C ^b   Degoul, F ^b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

^c CENTRE JEAN PERRIN   (France)

Author keywords

Anticancer drugs; Cell cycle; Mass spectrometry; Prohibitin; Protein alkylation; Protein targets

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; CELL PROTEIN; CYCLOHEXYLPHENYLCHLOROETHYLUREA; IODINE 125; IODOPHENYLCHLOROETHYLUREA; PHENYLCHLOROETHYLUREA; PROHIBITIN; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ALKYLATION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FLOW CYTOMETRY; ISOTOPE LABELING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ALKYLATING AGENTS; ALKYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARTIC ACID; CARBON RADIOISOTOPES; CELL CYCLE; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLOW CYTOMETRY; G1 PHASE; IMMUNOBLOTTING; IODINE RADIOISOTOPES; MOLECULAR STRUCTURE; PROTEOMICS; REPRESSOR PROTEINS; S PHASE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUBULIN; UREA; VOLTAGE-DEPENDENT ANION CHANNELS;

EID: 35348916581     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707415     Document Type: Article

References (22)

1. Bouchon B, Chambon C, Mounetou E, Papon J, Miot-Noirault E, Gaudreault RC et al. (2005). Alkylation of beta-tubulin on Glu 198 by a microtubule disrupter. Mol Pharmacol 68: 1415-1422.
2. Debiton E, Madelmont JC, Legault J, Barthomeuf C (2003). Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion. Cancer Chemother Pharmacol 51: 474-482.
3. Fortin S, Moreau E, Patenaude A, Desjardins M, Lacroix J, Rousseau JL et al. (2007). N-Phenyl-N′-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: role of omega-hydroxyl group in the covalent binding to beta-tubulin. Bioorg Med Chem 15: 1430-1438.
4. Freedman RB, Klappa P, Ruddock LW (2002). Protein disulfide isomerases exploit synergy between catalytic and specific binding domains. EMBO Rep 3: 136-140.
5. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S (2003). Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 278: 47853-47861.
6. Gaudreault RC, Alaui-Jamali MA, Batist G, Bechard P, Lacroix J, Poyet P (1994). Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumor cells. Cancer Chemother Pharmacol 33: 489-492.
7. Joshi B, Ko D, Ordonez-Ercan D, Chellappan SP (2003). A putative coiled-coil domain of prohibitin is sufficient to repress E2F1-mediated transcription and induce apoptosis. Biochem Biophys Res Commun 312: 459-466.
8. Lacroix J, Gaudreault RC, Page M, Joly LP (1988). In vitro and in vivo activity of 1-aryl-3-(2-chloroethyl) urea derivatives as new antineoplastic agents. Anticancer Res 8: 595-598.
9. Legault J, Gaulin JF, Mounetou E, Bolduc S, Lacroix J, Poyet P et al. (2000). Microtubule disruption induced in vivo by alkylation of beta-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res 60: 985-992.
10. Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER (2003). Tumor suppression by the prohibitin gene 3′ untranslated region RNA in human breast cancer. Cancer Res 63: 5251-5256.
11. Miot-Noirault E, Legault J, Cachin F, Mounetou E, Degoul F, Gaudreault RC et al. (2004). Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma. Invest New Drugs 22: 369-378.
12. Mishra S, Murphy LC, Murphy LJ (2006). The Prohibitins: emerging roles in diverse functions. J Cell Mol Med 10: 353-363.
13. Mishra S, Murphy LC, Nyomba BL, Murphy LJ (2005). Prohibitin: a potential target for new therapeutics. Trends Mol Med 11: 192-197.
14. Mounetou E, Legault J, Lacroix J, Gaudreault RC (2001). Antimitotic antitumor agents: synthesis, structure-activity relationships, and biological characterization of N-aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents. J Med Chem 44: 694-702.
15. Mounetou E, Legault J, Lacroix J, Gaudreault RC (2003). A new generation of N-aryl-N′-(1-alkyl-2-chloroethyl)ureas as microtubule disrupters: synthesis, antiproliferative activity, and betatubulin alkylation kinetics. J Med Chem 46: 5055-5063.
16. Nijtmans LG, Artal SM, Grivell LA, Coates PJ (2002). The mitochondrial PHB complex: roles in mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life Sci 59: 143-155.
17. Nijtmans LG, de Jong L, Artal Sanz M, Coates PJ, Berden JA, Back JW et al. (2000). Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J 19: 2444-2451.
18. Peng X, Mehta R, Wang S, Chellappan S, Mehta RG (2006). Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res 66: 7361-7369.
19. Petitclerc E, Deschesnes RG, Cote MF, Marquis C, Janvier R, Lacroix J et al. (2004). Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Cancer Res 64: 4654-4663.
20. Rastogi S, Joshi B, Fusaro G, Chellappan S (2006). Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism. J Biol Chem 281: 2951-2959.
21. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A et al. (2004). Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428: 198-202.
22. Wang S, Zhang B, Faller DV (2004). BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J 23: 2293-2303.